Trial Profile
A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Tetravalent Recombinant Subunit Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Dengue subunit vaccine (Primary) ; Aluminium hydroxide
- Indications Dengue
- Focus Pharmacodynamics
- 31 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 25 May 2015 New trial record